Melissa J. Moore

Melissa J. Moore
Born
New Market, Virginia, US
SpouseJanet Kosloff
Academic background
EducationBS, Chemistry, 1984, College of William and Mary
PhD, Biological Chemistry, 1989, Massachusetts Institute of Technology
ThesisMercuric ion reductase: mutagenesis of N- and C-terminal paired cysteines and initial crystallization studies (1989)
Doctoral advisorChristopher T. Walsh
Phillip Allen Sharp (postdoc)
Academic work
InstitutionsModerna
University of Massachusetts Chan Medical School
Brandeis University

Melissa J. Moore is an American biochemist who focuses on RNA. She was the Chief Scientific Officer of Moderna from 2016-2023, where her team contributed to the development of the Moderna COVID-19 vaccine.

Early life and education

Moore was born and raised in New Market, Virginia,[1] the youngest of four children.[2] After graduating from the College of William and Mary with a Bachelor of Science degree in Chemistry and Biology, she earned her PhD in Biological Chemistry from the Massachusetts Institute of Technology in 1989.[1] She wrote her thesis on "Mercuric ion reductase: mutagenesis of n- and c-terminal paired cysteines and initial crystallization studies".[3] As a Helen Hay Whitney postdoctoral fellow under the supervision of Phillip Allen Sharp, she invented technology to join long RNA molecules,[4] and published a seminal paper establishing the chemical mechanism of pre-mRNA splicing.[5]

Career

Brandeis University

Following her postdoctoral fellowship, Moore joined the faculty at Brandeis University in 1994, despite being recruited by Harvard University, Yale University, and Northwestern University.[6] Soon after, she was named a Searle Scholar and Packard Fellow.[7][8] At Brandeis, Moore established her own laboratory in the Biochemistry Department to research pre-mRNA splicing and its connections to intracellular mRNA localization, translation, and degradation. In 1997, she became a Howard Hughes Medical Institute Investigator, a position she retained for the following 19 years.

UMass Medical School

In 2007, Moore moved her research group to the Biochemistry and Molecular Pharmacology Department at the University of Massachusetts Chan Medical School (UMass Med).[9][10] In 2011, Moore was the recipient of the American Society for Biochemistry and Molecular Biology's William C. Rose Award[11] for excellence in mentoring. That year, Moore and her collaborator Ananth Karumanchi, also received a Bill and Melinda Gates Foundation Grand Challenges grant for their project "siRNA-based Therapeutics for Preeclampsia."[12] They received a second grant in 2013 to refine the therapy and test it in baboons.[13] That work stemmed from Moore's own experience as a preeclampsia survivor in 2003.[14]

Moderna

In October 2016, Moore was appointed Chief Scientific Officer, Platform Research, at Moderna Therapeutics.[15][16] While serving in this role, she was elected to the National Academy of Sciences,[17] named a fellow in the American Academy of Arts and Sciences, and recognized with the 2021 RNA Society Lifetime Achievement in Science Award.[18] During the COVID-19 pandemic, the work of Moore's team was instrumental in the development of the Moderna COVID-19 vaccine.[19] In December 2020, she and other Moderna leaders addressed the Food and Drug Administration advisory panel to consider recommending emergency use authorization of the mRNA-1273 vaccine.[2]

Personal life

Moore is married to Janet Kosloff, a retired CEO and entrepreneur in the life science market research sector. They have three children.[2]

References

  1. ^ a b "Melissa J. Moore". National Academy of Science. Retrieved November 2, 2021.
  2. ^ a b c Eshleman, Tina (December 15, 2020). "THE SCIENCE BEHIND THE VACCINE". College of William and Mary. Retrieved November 2, 2021.
  3. ^ Mercuric ion reductase: mutagenesis of n- and c-terminal paired cysteines and initial crystallization studies. WorldCat. OCLC 20337577. Retrieved November 2, 2021.
  4. ^ Moore, Melissa J.; Sharp, Phillip A. (1992-05-15). "Site-Specific Modification of Pre-mRNA: the 2′-Hydroxyl Groups at the Splice Sites". Science. 256 (5059): 992–997. Bibcode:1992Sci...256..992M. doi:10.1126/science.1589782. PMID 1589782.
  5. ^ Moore, Melissa J.; Sharp, Phillip A. (September 1993). "Evidence for two active sites in the spliceosome provided by stereochemistry of pre-mRNA splicing". Nature. 365 (6444): 364–368. Bibcode:1993Natur.365..364M. doi:10.1038/365364a0. ISSN 1476-4687. PMID 8397340. S2CID 4361512.
  6. ^ Yemma, John (March 6, 1997). "Short history, high standing". The Boston Globe. Retrieved November 2, 2021 – via newspapers.com.
  7. ^ "Melissa J. Moore". Searle Scholars Program. Retrieved November 2, 2021.
  8. ^ "Melissa J. Moore: 1994 Fellow". David and Lucile Packard Foundation. Retrieved November 2, 2021.
  9. ^ "UMass lures top talent". The Boston Globe. September 10, 2007. Retrieved November 2, 2021 – via newspapers.com.
  10. ^ "Melissa Moore, HHMI Investigator joins BMP Faculty". University of Massachusetts Chan Medical School. April 3, 2009. Retrieved November 2, 2021.
  11. ^ "Scientific community recognizes UMass med school researcher, mentor". Eurekalert. April 7, 2011. Retrieved November 2, 2021.
  12. ^ "Melissa Moore wins Gates Foundation grant". University of Massachusetts Chan Medical School. April 29, 2011. Retrieved November 2, 2021.
  13. ^ Turanov, Anton A.; Lo, Agnes; Hassler, Matthew R.; Makris, Angela; Ashar-Patel, Ami; Alterman, Julia F.; Coles, Andrew H.; Haraszti, Reka A.; Roux, Loic; Godinho, Bruno M. D. C.; Echeverria, Dimas (December 2018). "RNAi modulation of placental sFLT1 for the treatment of preeclampsia". Nature Biotechnology. 36 (12): 1164–1173. doi:10.1038/nbt.4297. ISSN 1546-1696. PMC 6526074. PMID 30451990.
  14. ^ Johnson, Charles Y. (November 30, 2013). "Chance meeting leads to novel preeclampsia treatment". The Boston Globe. Archived from the original on December 7, 2013. Retrieved November 2, 2021.
  15. ^ "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines". www.science.org. Retrieved 2022-02-24.
  16. ^ "Melissa Moore to join Moderna as chief scientific officer". University of Massachusetts Chan Medical School. September 13, 2016. Retrieved November 2, 2021.
  17. ^ "Melissa Moore elected to National Academy of Sciences". University of Massachusetts Chan Medical School. May 2, 2017. Retrieved November 2, 2021.
  18. ^ "2021 RNA Society Lifetime Achievement in Science Award". RNA Society. January 30, 2020. Retrieved November 2, 2021.
  19. ^ Bluestein, Adam (August 10, 2021). "How a Moderna scientist and her team pivoted to make a COVID-19 vaccine". Fast Company. Retrieved November 2, 2021.